Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO

MT Newswires Live01-02

Gan & Lee Pharmaceuticals (SHA:603087) has removed Sun Cheng from his positions as chief financial officer and vice general manager, according to a Thursday filing with the Shanghai Stock Exchange.

The company said Sun's dismissal is a "strategic measure" designed to "optimize and adjust senior management personnel based on the company's strategic need for global upgrading of its innovative drug R&D, marketing, and investment and financing businesses."

The Chinese pharmaceutical company subsequently appointed Zhou Li as acting CFO, effective immediately, until a new CFO is appointed.

Zhou joined Gan & Lee's finance department in 2012 and has served as the director of the company's finance department since October 2019.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment